EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research

Youngbo Choi, Youbeen Choi iD, Surin Hong

Pharmaceutics · 03.02.2024 · 16 (2) · 221

DOI: 10.3390/pharmaceutics16020221 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.02.2024. Verfasst von Youngbo Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Safety Engineering, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Technology and Information Promotion Agency for SMEs, Ministry of SMEs and Startups.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in cancer incidence has driven increased investment in anticancer agents, resulting in significant growth in the ADC therapy market. Over the past two decades, notable progress has been made, with approvals for 14 ADC treatments targeting various cancers by 2022. Diverse ADC therapies for hematologic malignancies and solid tumors have emerged, with numerous candidates currently undergoing clinical trials. Recent years have seen a noteworthy increase in ADC therapy clinical trials, marked by the initiation of numerous new therapies in 2022. Research and development, coupled with patent applications, have intensified, notably from major companies like Pfizer Inc. (New York, NY, USA), AbbVie Pharmaceuticals Inc. (USA), Regeneron Pharmaceuticals Inc. (Tarrytown, NY, USA), and Seagen Inc. (Bothell, WA, USA). While ADC therapy holds great promise in anticancer treatment, challenges persist, including premature payload release and immune-related side effects. Ongoing research and innovation are crucial for advancing ADC therapy. Future developments may include novel conjugation methods, stable linker designs, efficient payload delivery technologies, and integration with nanotechnology, driving the evolution of ADC therapy in anticancer treatment.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugates (ADCs)innovationintellectual property (IP) landscapekey playersmarkettechnology trends

Autor:innen und Institutionen

  • Department of Safety Engineering, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea.
  • Department of BigData, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea.
  • Department of Biotechnology, CHA University, Pocheon 11160, Gyeonggi, Republic of Korea.

ORCID-Profile: Youbeen Choi

Förderung

  • National Research Foundation of Korea
  • Korea Technology and Information Promotion Agency for SMEs
  • Ministry of SMEs and Startups

Zitieren

APA

Choi, Y., Choi, Y., & Hong, S. (2024). Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research. Pharmaceutics, 16(2), 221. https://doi.org/10.3390/pharmaceutics16020221

Vancouver

Choi Y, Choi Y, Hong S. Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research. Pharmaceutics. 2024;16(2):221. doi:10.3390/pharmaceutics16020221

BibTeX
@article{Choi2024,
  author = {Choi, Youngbo and Choi, Youbeen and Hong, Surin},
  title = {Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {221},
  doi = {10.3390/pharmaceutics16020221}
}
Kostenlos starten →